SCHEMBL674860

SCHEMBL674860

C=C(c1ccc2[nH]c3ncc(Cl)cc3c2c1)c1ccccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAP2 P11137 1/20 0.37
CCKBR P32239 1/20 0.36
JAK2 O60674 1/20 0.34
PRSS12 P56730 2/20 0.34
POLB P06746 1/20 0.34
CTNNB1 P35222 1/20 0.34
WNT3A P56704 1/20 0.34
PTK6 Q13882 2/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
ERBB2 P04626 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664375 0.84 MAP2 (0.43) MAP2CCKBRJAK2PTK6RAB9A
SCHEMBL675228 0.81 LMNA (0.36) SMN1; SMN2PRSS12POLBCTNNB1WNT3A
SCHEMBL676840 0.81 AURKA (0.42) PTK6RAB9AERBB2
SCHEMBL3728420 0.80 GABRP (0.35) SMN1; SMN2ALDH1A1RAB9AGABRPGABRD
SCHEMBL676843 0.80 CHEK1 (0.35) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL675106 0.79 KDR (0.36) TDP1ALDH1A1RAB9A
SCHEMBL676244 0.78 CTNNB1 (0.34) SMN1; SMN2POLBCTNNB1WNT3AALDH1A1
SCHEMBL676185 0.78 ERBB2 (0.38) POLBPTK6ERBB2
SCHEMBL3722919 0.77 KDM4E (0.33) SMN1; SMN2ALDH1A1RAB9AGABRPGABRD
SCHEMBL3399361 0.77 ALK (0.43) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 SMN1; SMN2 3499/4885TDP1 2082/4885MAP2 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.